Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
6
×
cancer
6
×
life sciences
national blog main
national top stories
novartis
6
×
san francisco blog main
san francisco top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
new york blog main
new york top stories
pfizer
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
eli lilly
europe blog main
europe top stories
roche
startups
abbvie
accent therapeutics
alexion pharmaceuticals
alzheimer's disease
amgen
What
bio
roundup
drug
new
cancer
developing
fda
ipo
life
medicines
science
acquisitions
activity
address
advantages
approval
approvals
approves
bails
bar
biggest
biogen
blood
blueprint
brand
bridgebio
brings
broader
build
buy
capital
car
carries
ceo
certain
clamped
company
company’s
covid
daniel
Language
unset
6
×
Current search:
novartis
×
unset
×
cancer
×
" boston top stories "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
